Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Sukki Cho, MD, Kyung-Min Ryu, MD, Yoon-Jin Hwang, MD, Eung Bae Lee, MD

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD Journal of Thoracic Oncology

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib Nobukazu Agatsuma, MD Journal of.

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Chasing Therapeutic Targets in Thymic Malignancies: Finding Needles in the Haystack to Frame a Comprehensive Canvas? Nicolas Girard, MD Journal of Thoracic.

Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis Hyun Lee, MD,

Evaluation of Kras Gene Mutation and Copy Number in Thymic Carcinomas and Thymomas Hidefumi Sasaki, MD, PhD, Motoki Yano, MD, PhD, Yoshitaka Fujii, MD,

A Case of Heart Failure after Treatment with Anti–PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient

Germline Mutations in DNA Repair Genes in Lung Adenocarcinoma

Electronic Updates for JTO Readers

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors Hsin-Yi Wang, MD Journal of Thoracic.

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Charles M. Rudin, MD, PhD, Alexander Drilon, MD, J.T. Poirier, PhD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after.

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

A Primer on Health Economic Evaluations in Thoracic Oncology

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Nivolumab-Induced Granulomatous Inflammation of the Pleura

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Genetic Changes in Squamous Cell Lung Cancer: A Review

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer Elena Bolzacchini, MD,

S-1 Treatment for Chemorefractory Thymic Carcinoma

PS01.07 The Clinical Necessity of Extended Thymectomy for Thymic Squamous Cell Carcinomas Revealed by Exome Sequencing J. Jiang, Y. Zhang, C. Jin, J.

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune.

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Mutation Ensemble for Response to Programmed Cell Death 1 Inhibition in Thymic Carcinoma Hyun-Sung Lee, MD, PhD, Cynthia Y. Truong, BS, Bryan M. Burt, MD Journal of Thoracic Oncology Volume 13, Issue 8, Pages e150-e152 (August 2018) DOI: 10.1016/j.jtho.2018.03.027 Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Mutation ensemble for response to PD-1 inhibition in thymic carcinoma. (A) TMB by targeted sequencing of 206 genes is highly correlated with TMB by WES in thymic epithelial tumors in TCGA database. TMB by targeted sequencing showed higher correlation with TMB by WES in thymic carcinoma. (B) TMB in thymic carcinoma (n = 35) does not predict response to anti–PD-1 treatment. (C) cyclin dependent kinase inhibitor 1B (CDKN1B), CYLD lysine 63 deubiquitinase (CYLD), and SET domain containing 2 (SETD2) mutations were associated with objective response to pembrolizumab, but BAP1, GTF2I, IGF2R, and TP53 were associated with poor response. Mutational status of seven genes was mutually exclusive. CR, complete response; PD progressive disease; PD-1, programmed cell death 1; PR partial response; SD stable disease; TC, thymic carcinoma; TCGA, The Cancer Genome Atlas; TMB, tumor mutation burden; TET, thymic epithelial tumor; WES whole exome sequencing. Journal of Thoracic Oncology 2018 13, e150-e152DOI: (10.1016/j.jtho.2018.03.027) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions